Apolipoproteins and contactin 5 are proteins associated with Alzheimer’s disease (AD) pathophysiology. Apolipoproteins act on transport and clearance of cholesterol and phospholipids during synaptic turnover and terminal proliferation. Contactin 5 is a neuronal membrane protein involved in key processes of neurodevelopment.
Objective:
To investigate the interactions between contactin 5 and apolipoproteins in AD, and the role of these proteins in response to neuronal damage.
Methods:
Apolipoproteins (measured by Luminex), contactin 5 (measured by Olink’s proximity extension assay), and cholesterol (measured by liquid chromatography mass spectrometry) were assessed in the cerebrospinal fluid (CSF) and plasma of cognitively unimpaired participants (n = 93). Gene expression was measured using polymerase chain reaction in the frontal cortex of autopsied-confirmed AD (n = 57) and control subjects (n = 31) and in the hippocampi of mice following entorhinal cortex lesions.
Results:
Contactin 5 positively correlated with apolipoproteins B (p = 5.4×10–8), D (p = 1.86×10–4), E (p = 2.92×10–9), J (p = 2.65×10–9), and with cholesterol (p = 0.0096) in the CSF, and with cholesterol (p = 0.02), HDL (p = 0.0143), and LDL (p = 0.0121) in the plasma. Negative correlations were seen between CNTN5, APOB (p = 0.034) and APOE (p = 0.015) mRNA levels in the brains of control subjects. In the mouse model, apoe and apoj gene expression increased during the reinnervation phase (p < 0.05), while apob (p = 0.023) and apod (p = 0.006) increased in the deafferentation stage.
Conclusions:
Extensive interactions were observed between contactin 5 and apolipoproteins and cholesterol, possibly due to neuronal damage. The alterations in gene expression of apolipoproteins suggest a role in axonal, terminal, and synaptic remodeling in response to entorhinal cortex damage.
LeducV, Jasmin-BélangerS, PoirierJ (2010) APOE and cholesterol homeostasis in Alzheimer’s disease. Trends Mol Med16, 469–477.
4.
PoirierJ, DelisleMC, QuirionR, AubertI, FarlowM, LahiriD, HuiS, BertrandP, NalbantogluJ, GilfixBM, GauthierS (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A92, 12260–12264.
5.
TerrisseL, PoirierJ, BertrandP, MerchedA, VisvikisS, SiestG, MilneR, RassartE (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients. J Neurochem71, 1643–1650.
6.
WingoTS, CutlerDJ, WingoAP, LeNA, RabinoviciGD, MillerBL, LahJJ, LeveyAI (2019) Association of early-onset Alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB. JAMA Neurol76, 809–817.
7.
PicardC, NilssonN, LabonteA, AuldD, Rosa-NetoP,
Alzheimer’s Disease Neuroimaging InitiativeAshtonNJ, ZetterbergH, BlennowK, BreitnerJCB, VilleneuveS, PoirierJ, PREVENT-ADresearch group (2022) Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease. Alzheimers Dement18, 875–887.
8.
WisniewskiT, GolabekA, MatsubaraE, GhisoJ, FrangioneB (1993) Apolipoprotein E: Binding to soluble Alzheimer’s beta-amyloid. Biochem Biophys Res Commun192, 359–365.
9.
RodriguezGA, TaiLM, LaDuMJ, RebeckGW (2014) Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation11, 111.
10.
BeffertU, CohnJS, Petit-TurcotteC, TremblayM, AumontN, RamassamyC, DavignonJ, PoirierJ (1999) Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer’s disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res843, 87–94.
PoirierJ, DavignonJ, BouthillierD, KoganS, BertrandP, GauthierS (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342, 697–699.
13.
StrittmatterWJ, RosesAD (1995) Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A92, 4725–4727.
14.
ZhuR, LiuX, HeZ (2018) Association between CLU gene rs11136000 polymorphism and Alzheimer’s disease: An updated meta-analysis. Neurol Sci39, 679–689.
15.
LambertJ-C, HeathS, EvenG, CampionD, SleegersK, HiltunenM, CombarrosO, ZelenikaD, BullidoMJ, TavernierB, LetenneurL, BettensK, BerrC, PasquierF, FiévetN, Barberger-GateauP, EngelborghsS, De DeynP, MateoI, FranckA, HelisalmiS, PorcelliniE, HanonO, European Alzheimer’s Disease InitiativeI, de PancorboMM, LendonC, DufouilC, JaillardC, LeveillardT, AlvarezV, BoscoP, MancusoM, PanzaF, NacmiasB, BossùP, PiccardiP, AnnoniG, SeripaD, GalimbertiD, HannequinD, LicastroF, SoininenH, RitchieK, BlanchéH, DartiguesJ-F, TzourioC, GutI, Van BroeckhovenC, AlpérovitchA, LathropM, AmouyelP (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet41, 1094–1099.
16.
GlocknerF, OhmTG (2003) Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype. Neuroscience122, 103–110.
17.
MercatiO, DanckaertA, Andre-LerouxG, BellinzoniM, GouderL, WatanabeK, ShimodaY, GrailheR, De ChaumontF, BourgeronT, Cloez-TayaraniI (2013) Contactin 4, -5 and -6 differentially regulate neuritogenesis while they display identical PTPRG binding sites. Biol Open2, 324–334.
18.
ToyoshimaM, SakuraiK, ShimazakiK, TakedaY, NakamotoM, SerizawaS, ShimodaY, WatanabeK (2009) Preferential localization of neural cell recognition molecule NB-2 in developing glutamatergic neurons in the rat auditory brainstem. J Comp Neurol513, 349–362.
19.
DauarMT, LabonteA, PicardC, MironJ, Rosa-NetoP, ZetterbergH, BlennowK, VilleneuveS, PoirierJ (2023) Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer’s disease spectrum. Alzheimers Dement19, 2816–2830.
20.
BreitnerJCS, PoirierJ, EtiennePE, LeoutsakosJM (2016) Rationale and structure for a new center for Studies on Prevention of Alzheimer’s Disease (StoP-AD). J Prev Alzheimers Dis3, 236–242.
21.
Tremblay-MercierJ, MadjarC, DasS, Pichet BinetteA, DykeSOM, EtienneP, Lafaille-MagnanME, RemzJ, BellecP, Louis CollinsD, Natasha RajahM, BohbotV, LeoutsakosJM, Iturria-MedinaY, KatJ, HogeRD, GauthierS, TardifCL, Mallar ChakravartyM, PolineJB, Rosa-NetoP, EvansAC, VilleneuveS, PoirierJ, BreitnerJCS, PREVENT-AD Research Group
(2021) Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease. Neuroimage Clin31, 102733.
22.
KhachaturianZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol42, 1097–1105.
23.
LeducV, TherouxL, DeaD, DufourR, PoirierJ (2016) Effects of rs3846662 variants on HMGCR mRNA and protein levels and on markers of Alzheimer’s disease pathology. J Mol Neurosci58, 109–119.
24.
BlainJ-F, ParadisE, GaudreaultSB, ChampagneD, RichardD, PoirierJ (2004) A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neurobiol Dis15, 510–519.
25.
LambertJC, Ibrahim-VerbaasCA, HaroldD, NajAC, SimsR, BellenguezC, DeStafanoAL, BisJC, BeechamGW, Grenier-BoleyB, et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet45, 1452–1458.
BellenguezC, KucukaliF, JansenIE, KleineidamL, Moreno-GrauS, AminN, NajAC, Campos-MartinR, Grenier-BoleyB, AndradeV, et al (2022) New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet54, 412–436.
28.
DafnisI, RaftopoulouC, MountakiC, MegalouE, ZannisVI, ChroniA (2018) ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and Abeta production independently of their cholesterol efflux capacity. Biochem J475, 1839–1859.
MaezawaI, JinLW, WoltjerRL, MaedaN, MartinGM, MontineTJ, MontineKS (2004) Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem91, 1312–1321.
31.
NarayanP, OrteA, ClarkeRW, BolognesiB, HookS, GanzingerKA, MeehanS, WilsonMR, DobsonCM, KlenermanD (2011) The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1–40) peptide. Nat Struct Mol Biol19, 79–83.
32.
OdaT, WalsP, OsterburgHH, JohnsonSA, PasinettiGM, MorganTE, RozovskyI, StineWB, SnyderSW, HolzmanTF (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol136, 22–31.
NavaC, KerenB, MignotC, RastetterA, Chantot-BastaraudS, FaudetA, FonteneauE, AmietC, LaurentC, JacquetteA, WhalenS, AfenjarA, PérisseD, DoummarD, DorisonN, LeboyerM, SiffroiJ-P, CohenD, BriceA, HéronD, DepienneC (2014) Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders. Eur J Hum Genet22, 71–78.
35.
van DaalenE, KemnerC, VerbeekNE, van der ZwaagB, DijkhuizenT, RumpP, HoubenR, van ‘t SlotR, de JongeMV, StaalWG, BeemerFA, VorstmanJAS, BurbachJPH, van AmstelHKP, HochstenbachR, BrilstraEH, PootM (2011) Social Responsiveness Scale-aided analysis of the clinical impact of copy number variations in autism. Neurogenetics12, 315–323.
36.
ChatterjeeM, Del CampoM, MorremaTHJ, de WaalM, van der Flier WM, HoozemansJJM, TeunissenCE (2018) Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease. Alzheimers Res Ther10, 52.
37.
Oguro-AndoA, ZukoA, KleijerKTE, BurbachJPH (2017) A current view on contactin-4, -5, and -6: Implications in neurodevelopmental disorders. Mol Cell Neurosci81, 72–83.
38.
MohebianyAN, HarrochS, BouyainS (2014) New insights into the roles of the contactin cell adhesion molecules in neural development. Adv Neurobiol8, 165–194.
39.
KleijerKTE, van NieuwenhuizeD, SpierenburgHA, Gregorio-JordanS, KasMJH, BurbachJPH (2018) Structural abnormalities in the primary somatosensory cortex and a normal behavioral profile in Contactin-5 deficient mice. Cell Adh Migr12, 5–18.
40.
LiH, TakedaY, NikiH, OgawaJ, KobayashiS, KaiN, AkasakaK, AsanoM, SudoK, IwakuraY, WatanabeK (2003) Aberrant responses to acoustic stimuli in mice deficient for neural recognition molecule NB-2. Eur J Neurosci17, 929–936.
41.
AshrafiS, BetleyJN, ComerJD, Brenner-MortonS, BarV, ShimodaY, WatanabeK, PelesE, JessellTM, KaltschmidtJA (2014) Neuronal Ig/Caspr recognition promotes the formation of axoaxonic synapses in mouse spinal cord. Neuron81, 120–129.
42.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
43.
BaeriswylT, StoeckliET (2008) in-1/TAG-1 is required for pathfinding of granule cell
axon in the developing cerebellum. Neural Dev3, 7.
44.
WolmanMA, SittaramaneVK, EssnerJJ, YostHJ, ChandrasekharA, HalloranMC (2008) Transient al glycoprotein-1 (TAG-1) and laminin-alpha1 regulate dynamic growth cone behaviors and initial axon direction. Neural Dev3, 6.
45.
PengYR, TranNM, KrishnaswamyA, KostadinovD, MartersteckEM, SanesJR (2017) Satb1 regulates contactin 5 to pattern dendrites of a mammalian retinal ganglion cell. Neuron95, 869–883e866.
46.
PoirierJ (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci17, 525–530.
47.
PoirierJ, BaccichetA, DeaD, GauthierS (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience55, 81–90.
48.
ZarowC, VictoroffJ (1998) Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol149, 79–86.
49.
ChampagneD, RochfordJ, PoirierJ (2005) Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: Role of the astroglial response. Exp Neurol194, 31–42.
50.
WhiteF, NicollJA, RosesAD, HorsburghK (2001) Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis8, 611–625.
